INFLARX N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.54 USD | -5.52% |
|
+23.20% | -5.52% |
| May. 08 | InflaRx N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 21 | Transcript : InflaRx N.V. - Special Call |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 407K 442K | Sales 2025 * | 1.37M 1.49M | Capitalization | 83.49M 90.74M |
|---|---|---|---|---|---|
| Net income 2024 * | -46M -49.99M | Net income 2025 * | -61M -66.3M | EV / Sales 2024 * | 78.5 x |
| Net cash position 2024 * | 51.55M 56.03M | Net cash position 2025 * | 7.3M 7.93M | EV / Sales 2025 * | 55.6 x |
| P/E ratio 2024 * |
-1.92
x | P/E ratio 2025 * |
-1.65
x | Employees | 62 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on InflaRx N.V.
More recommendations
More press releases
More news
| 1 day | -5.52% | ||
| 1 week | +23.20% | ||
| Current month | +12.41% | ||
| 1 month | +14.07% | ||
| 3 months | +0.65% | ||
| 6 months | +1.32% | ||
| Current year | -5.52% |
1 week
1.35
1.68
1 month
1.171.68
Current year
1.172.10
1 year
1.144.70
3 years
0.787.25
5 years
0.7842.99
10 years
0.7853.10
| Managers | Title | Age | Since |
|---|---|---|---|
Renfeng Guo
FOU | Founder | 53 | 07-11-30 |
Niels Riedemann
FOU | Founder | 51 | 07-11-30 |
Thomas Taapken
DFI | Director of Finance/CFO | 59 | 20-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Nicolas Fulpius
FOU | Founder | 51 | 07-11-30 |
Niels Riedemann
FOU | Founder | 51 | 07-11-30 |
Renfeng Guo
FOU | Founder | 53 | 07-11-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-20 | 1.54 | -5.52% | 158,298 |
| 24-05-17 | 1.63 | +12.41% | 484,006 |
| 24-05-16 | 1.45 | +3.57% | 52,356 |
| 24-05-15 | 1.4 | -2.10% | 82,515 |
| 24-05-14 | 1.43 | +14.40% | 300,648 |
Delayed Quote Nasdaq, May 20, 2024 at 04:00 pm EDT
More quotes
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Calendar
2024-06-05
- R&D Day
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.418
EUR
Average target price
8.375
EUR
Spread / Average Target
+490.65%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.52% | 90.68M | |
| +9.58% | 115B | |
| +12.41% | 107B | |
| -3.41% | 21.6B | |
| -12.38% | 22.31B | |
| -6.87% | 19.19B | |
| -3.35% | 18.23B | |
| -38.57% | 17.62B | |
| +7.51% | 14.26B | |
| +35.67% | 12.37B |
- Stock Market
- Equities
- IFRX Stock